Allarity Therapeutics, Inc.
ALLR
$1.08
$0.0050.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.12% | -17.84% | 0.24% | 7.24% | 0.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -0.38% | -6,808.33% | -565.29% | -211.28% | -211.28% |
| Total Operating Expenses | 2.39% | -2.18% | 8.63% | 8.88% | 1.40% |
| Operating Income | -2.39% | 2.18% | -8.63% | -8.88% | -1.40% |
| Income Before Tax | -110.66% | -43.26% | 16.85% | 25.93% | 32.77% |
| Income Tax Expenses | -559.04% | 1.65% | 126.51% | 126.87% | 105.46% |
| Earnings from Continuing Operations | -105.99% | -44.30% | 14.45% | 24.12% | 25.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.99% | -44.30% | 14.45% | 24.12% | 25.89% |
| EBIT | -2.39% | 2.18% | -8.63% | -8.88% | -1.40% |
| EBITDA | -2.56% | 2.10% | -8.72% | -9.01% | -1.54% |
| EPS Basic | -- | -- | -302.64% | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -300.42% | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -93.83% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |